Pain has long been known to be one of the five cardinal signs of inflammation, but only in the past decades have we begun to understand the close correlations between the immune and nervous systems in the generation of pain. Historically, autoantibodies have been connected to chronic pain through their ability to promote tissue damage and inflammatory reactions. However, the role of autoantibodies as mediators of pain via non-inflammatory mechanisms, whereby they may target sensory neurons directly or indirectly, has recently become a major focus in the field. Indeed, autoantibodies purified from patients with rheumatoid arthritis (RA) (Wigerblad et al., 2016) or complex regional pain syndrome (CRPS) (Té kus et al., 2014) were shown to induce pain-like behavior when injected into mice via indirect, non-inflammatory sensitization of pain fibers. Recent studies have also shown that antibodies can directly activate sensory neurons through either their constant (Fc) or antigen-binding (Fab) regions. In fact, autoantibodies in immune complex can directly stimulate pain fibers by binding to Fc gamma receptors (Qu et al., 2011) . Furthermore, pathogenic antibodies targeting neuronal surface antigens (NSAbs) were recently found to modulate the activity and properties of their neuronal targets, potentiating a multitude of possible aberrant effects. NSAbs targeting the voltage-gated potassium channel complex (VGKCC), which aids in bringing depolarized neurons back to resting potential, are currently a major interest as they have frequently been observed in patients exhibiting neuropathic pain (Irani et al., 2014) . Although originally discovered in patients with peripheral nerve hyperexcitability (PNH), these autoantibodies have recently been implicated in other neurological disorders with reported pain components, such as Morvan's syndrome. As the severity of symptoms highly correlates with serum titers of VGKCCs-Abs, patients often respond well to immunosuppressive therapy. However, in order to develop newer and safer therapeutics for patients, it is imperative to understand the mechanisms through which pathogenic autoantibodies elicit their effects.
VGKCC antibodies were first discovered by researchers attempting to isolate antibodies against the voltage-gated potassium channels (VGKCs) using patientderived antibodies to immunoprecipitate a-dendrotoxin-bound VGKCs from brain extracts. The potassium channels Kv1.1 and Kv1.2 were originally thought to be the targets of patient autoantibodies as they have previously been linked to neuropathic pain through modulation of action potential (AP) thresholds and frequencies, which results in neuronal hyperexcitability (Tsantoulas and McMahon, 2014) . However, it was later discovered that patient-derived autoantibodies were actually targeting the extracellular domains of leucine-rich glioma-inactivated 1 (LGI1) and contactin-associated protein 2 (CASPR2), which form a complex with solubilized VGKCs. Interestingly, 40% of patients seropositive for CASPR2-Abs report neuropathic pain, whereas only 15% of LGI1-seropositive patients report such, thus indicating that CASPR2 may play a larger role in the underlying driving factors of neuropathic pain in these patients (Binks et al., 2017) . CASPR2 is widely abundant in the peripheral and central nervous systems and is normally observed bound within the VGKCC at the juxtaparanodal region (JXP) of myelinated nerve fibers (see Figure 1A ). Previous studies have shown that VGKCs are aberrantly distributed along internodal segments in mice lacking CASPR2 protein, although this apparently did not affect the conduction velocity or other tested properties of optic nerve fibers (Poliak et al., 2003) .
In this issue of Neuron, Dawes et al. (2018) set out to determine how CASPR2-Abs may cause neuropathic pain and, in the process, developed the first model whereby patient-derived antibodies induced passive transfer of a neuropathic pain phenotype in mice. They first observed that CASPR2-Abs, purified from human patient sera, cause delayed onset mechanical hypersensitivity when systemically injected into healthy mice. CASPR2-Abs were isolated from two patients with reported neuropathic pain. In order to establish that their serum transfer model likely recapitulates the human disease state from which the antibodies came, Dawes et al. (2018) set out to evaluate the possible neuropathic origins of mechanical hypersensitivity. Indeed, they failed to find any signs of neuronal damage and exhausted the possibility of any gross inflammatory response. This, therefore, excluded that CASPR2-Abs were eliciting pain via similar mechanisms as those previously reported in RA and instead indicated a potentially novel neuropathic pain mechanism.
At this point, it was apparent that CASPR2-Abs likely induce pain through a direct neuronal action. Moreover, the observation that antibodies did not cross the blood-brain barrier as they were not found in the spinal cord led Dawes et al. (2018) to hypothesize a peripheral action. It was known that the antibodies were unlikely to have access to CASPR2 bound in VGKCCs at the JXP due to myelin ensheathing and isolating membranebound proteins from the extracellular environment. Importantly, Dawes et al. (2018) were able to determine that the CASPR2-Abs were actually binding to soma of dorsal root ganglia (DRG) neurons. Regardless of the lack of antibodies binding directly to sciatic nerve fibers, CASPR2 and Kv1.1 protein levels were significantly decreased in both soma and axons of sensory neurons ( Figure 1B) . From these first experiments, Dawes et al. (2018) were able to establish the hypothesis that CASPR2-Abs, binding on the soma of DRG neurons, reduce the amount of both CASPR2 and Kv1.1 within fibers, ultimately resulting in primary afferent hyperexcitability ( Figure 1C) .
Armed with the hypothesis from the above experiments, Dawes et al. (2018) were then able to employ alternative approaches to further parse out the mechanisms while decreasing the necessity for using the patient-derived antibodies. For instance, mice lacking the full-length version of CASPR2 (Cntnap2 À/À ) exhibited similar mechanical hypersensitivity, as well as increased supra-threshold thermal sensitivity, and increased painlike behaviors in response to chemical algogens. Thus, Dawes et al. (2018) deemed these mice to be suitable substitutes for CASPR2-Ab-injected mice for further studies.
Using As there are diverse subtypes of medium-sized DRG neurons, Dawes et al. (2018) then decided to identify the specific neuronal type(s) affected by Cntnap2 deletion by recording responses to a variety of specific stimuli from tibial nerve fibers that innervate the glabrous skin of the hindpaw. They only found differences in Ad fibers corresponding to the low-threshold D-hair mechanoreceptors, which exhibited hyperexcitability and increased firing rates.
In order to show that CASPR2 depletion-mediated hyperexcitability on primary afferents is a cell-autonomous phenomenon, Dawes et al. (2018) Finally, Dawes et al. (2018) were able to link all of the above studies back to the serum transfer models through the addition of patient-derived CASPR2-Abs to cultured DRGs, which mimicked the Cntnap2 À/À cultured DRGs in that they decreased membrane-bound Kv1.2, as well as the a-dendrotoxin-sensitive outward currents, resulting in increased neuronal excitability. Thus, Dawes et al. (2018) concluded that CASPR2-Ab injection in mice results in a peripheral neuropathic hypersensitivity through direct action on sensory neurons via decreased Kv1 channel function. The works highlighted above and published in this issue of Neuron by Dawes et al. (2018) employed a reverse translational approach in mice, depicting a causal relationship between patientderived pathogenic autoantibodies and pain. Injection of patient-derived sera into mice, for the first time, recapitulated a neuropathic pain state experienced by the human patient donors. The fact that autoantibodies alone can directly cause a channelopathy is impressive, but showing that patient-derived autoantibodies could cause this in mice is quite a leap forward for our ability to understand and treat disease. These types of serum transfer models have had similar success in two other painful inflammatory conditions: RA and CRPS. Thus, the clear and apparent results of this study further prove the efficacy of serum transfer models and their great translational potential for Ab-induced pain conditions as well as autoimmune disease in general.
This study also marks the first time a complete mechanism for CASPR2-Abinduced pain is shown experimentally. While the association of Kv1 potassium channels with pain, as well as the importance of CASPR2 for the correct localization of VGKCs, had been hypothesized, Dawes et al. (2018) were able to confirm that CASPR2 depletion led to hyperexcitable DRG neurons, and this also occurs when CASPR2-Abs bind specifically to the soma of the primary afferents. However, the mechanism through which Ab binding results in depletion of CASPR2 and Kv1 remains unknown, and understanding this may reveal a novel underlying biology of autoimmune disease. As such, this is a logical future line of research.
Moreover, Dawes et al. (2018) were able to specify hyperexcitability in a small subpopulation of primary afferents, those with D-hair mechanoreceptor terminals, as a potential driving force behind the Ab-induced pain. D-hair receptors are the most sensitive cutaneous mechanoreceptors as this population of lowthreshold Ad fibers have large receptive fields. However, the contribution of D-hair-expressing Ad fibers to pain is not well described, and work exploring the impact of this finding and how it relates to the clinical symptoms are warranted. In this model, hyperexcitability of D-hair fibers doesn't result in dynamic allodynia as one might expect, potentially showing that D-hair receptors on glabrous skin represent a novel primary afferent subtype distinct from those on hairy skin. Interestingly, CASPR2-Abs also bind to the cell bodies of small nociceptive C fibers, suggesting a broader action of these antibodies. This may be a line of future investigation as C fibers were previously speculated to be indirectly acted upon by CASPR2-Abs through central sensitization, but this may indicate a direct action.
The thoroughness of this work sets a precedent for future studies of its kind and represents a major advance in our mechanistic understanding of autoantibody-induced pain. From a wider perspective, this study is of relevance for the immunological field in general as it proves a hypothesized, but never before demonstrated, function of autoantibodies. On top of this, Dawes et al. (2018) 's results show the incredible translational potential of using patient-derived autoantibodies in basic research models. These models enable patients to directly contribute toward research, as well as open the doors of communication between patients, researchers, and physicians-something of great importance that is often underappreciated.
